Docetaxel in Non Small Cell Lung Cancer (NSCLC)

• Status: Completed
• Trial end date: 2009-10-01

Summary

Primary objective:

• To assess the response rate to induction therapy with docetaxel/CDDP.

Secondary objectives:

To assess

• Resectability after induction therapy

• Time to progression

• Overall survival

• Safety profile

• Quality of Life

• Phase: Phase 2

Details

• Lead Sponsor: Sanofi
• Treatments: Cisplatin; Docetaxel